LONDON--(BUSINESS WIRE)--Leading life science instrumentation company BJS Biotechnologies today announced it is to lead a London consortium to finalise development of a rapid POC (Point of Care) sepsis testing system. Called SEPSIS-xxpress the new system combines BJS’s excellence in sample preparation, automation and real-time PCR with Brunel University London’s microfluidic engineering skills, while St Georges, University of London, will run clinical trials. With an estimated 25 million annual cases of sepsis (blood poisoning) worldwide and over 37,000 avoidable deaths in the UK, the effective diagnosis of sepsis is a major unmet medical need. Delivering rapid actionable results in a POC setting will enable the correct antimicrobial treatment to be given, treatments that are tailored to the specific antibiotic-resistant pathogen(s). As well as dramatically improving patient outcomes, BJS Biotechnologies calculates SEPSIS-xxpress will save an average of 11 days in ICU per patient, a saving of £2 billion to the NHS alone.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
